Karuna Therapeutics Stock Forecast, Price & News

Karuna Therapeutics (NASDAQ:KRTX) Frequently Asked Questions

Is Karuna Therapeutics a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Karuna Therapeutics stock.
View analyst ratings for Karuna Therapeutics or view top-rated stocks.

How has Karuna Therapeutics' stock price been impacted by COVID-19?

Karuna Therapeutics' stock was trading at $78.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KRTX shares have increased by 36.9% and is now trading at $107.84.
View which stocks have been most impacted by COVID-19.

When is Karuna Therapeutics' next earnings date?

Karuna Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Karuna Therapeutics.

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) announced its earnings results on Thursday, November, 4th. The company reported ($1.72) EPS for the quarter, missing analysts' consensus estimates of ($1.47) by $0.25.
View Karuna Therapeutics' earnings history.

What price target have analysts set for KRTX?

13 analysts have issued 1 year price targets for Karuna Therapeutics' shares. Their forecasts range from $150.00 to $185.00. On average, they anticipate Karuna Therapeutics' share price to reach $167.58 in the next year. This suggests a possible upside of 55.4% from the stock's current price.
View analysts' price targets for Karuna Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Karuna Therapeutics' key executives?

Karuna Therapeutics' management team includes the following people:

• Steven Marc Paul, Chairman, President & Chief Executive Officer
• Andrew Miller, Chief Operating Officer
• Troy A. Ignelzi, Chief Financial Officer & Secretary (LinkedIn Profile)
• Stephen Brannan, Chief Medical Officer
• Ronald Marcus, Senior Vice President-Medical

Who are some of Karuna Therapeutics' key competitors?

Some companies that are related to Karuna Therapeutics include Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), United Therapeutics (UTHR), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Biohaven Pharmaceutical (BHVN), Organon & Co. (OGN), Grifols (GRFS), Maravai LifeSciences (MRVI), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Sarepta Therapeutics (SRPT) and Mirati Therapeutics (MRTX).
View all of KRTX's competitors.

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

When did Karuna Therapeutics IPO?

(KRTX) raised $70 million in an IPO on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Karuna Therapeutics' stock symbol?

Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."

Who are Karuna Therapeutics' major shareholders?

Karuna Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Catalyst Private Wealth LLC (0.08%), Allspring Global Investments Holdings LLC (0.02%), Russell Investments Group Ltd. (0.02%), Exane Derivatives (0.00%) and Lindbrook Capital LLC (0.00%). Company insiders that own Karuna Therapeutics stock include Andrew Craig Miller, Atul Pande, Edmund Harrigan, Heather Preston, James Healy, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends for Karuna Therapeutics.

Which major investors are buying Karuna Therapeutics stock?

KRTX stock was acquired by a variety of institutional investors in the last quarter, including Catalyst Private Wealth LLC, Allspring Global Investments Holdings LLC, Russell Investments Group Ltd., Exane Derivatives, and Lindbrook Capital LLC. Company insiders that have bought Karuna Therapeutics stock in the last two years include Heather Preston, James Healy, and Steven M Paul.
View insider buying and selling activity for Karuna Therapeutics or or view top insider-buying stocks.

How do I buy shares of Karuna Therapeutics?

Shares of KRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karuna Therapeutics' stock price today?

One share of KRTX stock can currently be purchased for approximately $107.84.

How much money does Karuna Therapeutics make?

Karuna Therapeutics has a market capitalization of $3.19 billion. The company earns $-68.55 million in net income (profit) each year or ($4.88) on an earnings per share basis.

How many employees does Karuna Therapeutics have?

Karuna Therapeutics employs 63 workers across the globe.

What is Karuna Therapeutics' official website?

The official website for Karuna Therapeutics is karunatx.com.

Where are Karuna Therapeutics' headquarters?

Karuna Therapeutics is headquartered at 33 ARCH STREET SUITE 3110, BOSTON MA, 02110.

How can I contact Karuna Therapeutics?

Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The company can be reached via phone at (857) 449-2244 or via email at [email protected].